摘要 |
A method for survival prediction in cancer patients is provided. In one embodiment, the survival prediction is determined by the presence or absence of KRAS gene region deletion and/or loss of Chromosome 12 (Ch. 12) in cancer tumor tissue. In another embodiment, the presence or absence of KRAS gene region deletion and/or loss of Ch. 12 in cancer tumor tissue is used to predict survival in non-small-cell lung cancer (NSCLC) patients. |